Comorbid Tuberculosis in the Context of the Formation of a Local Epidemic Situation

The aim of the study was to analyze epidemiological data on tuberculosis in the Kursk region, taking into account the changing socio-economic situation in the region, as well as to study the possibilities of using remaxol in the regimens of accompanying therapy for hepatotoxic reactions in patients with tuberculosis. During the analysis of the data array, it was noted that the dynamics of infectious processes were similar to the other regions of the Russian Federation: a decrease against the background of COVID-19 and a gradual increase in morbidity in the post-pandemic period. A third of the patients included in the study were diagnosed with comorbid forms of tuberculosis, characterized by greater severity of the disease and lower effectiveness of therapy: recovery (with deregistration) was recorded in half (49.8%) of patients with monoinfection, while in patients with a comorbid course of the disease, this figure was 35%. At the same time, clinical recovery was diagnosed in 38.2% of patients with monoinfection and in 47% of patients with comorbid tuberculosis (P<0.5). The inclusion of remaxol (intravenous drip, 400 ml/day, every other day — course No. 5, then 1 time per week No. 4) in the treatment regimens for hepatotoxic reactions during the main course of treatment in patients with tuberculosis, in both monoinfection and comorbid forms, contributed to a more rapid relief of deviations in clinical and laboratory parameters and an increase in the effectiveness of treatment: 84.2% in patients with tuberculosis and 85.7% with a comorbid form of tuberculosis versus 81.9% and 83.7% in patients in the comparison group (P≤0.05).

1. ОOn the strategy for the development of healthcare in the Russian Federation until 2025: Decree of the President of the Russian Federation of 06.06.2019 No. 254. Moscow, 12. (in Russian)

2. Nechaeva O. B. The state and prospects of the anti-tuberculosis service in Russia during COVID-19 Tuberkulez i Bolezni Legkikh. 2020; 98(12): 7–19]. doi: https://doi.org/10.21292/2075-1230-2020-98-12-7-19. (in Russian)

3. Azovtseva O. V., Gritsyuk A. V., Gemaeva M. D., Karpov A. V., Arkhipov G. S. HIV infection and tuberculosis as the most complex variant of comorbidity Vestnik Novgorodskogo Gosudarstvennogo Universiteta. 2020; 117 (1): 79–84. doi: https://doi.org/10.34680/2076-8052.2020.1(117).79-84. (in Russian)

4. Yablonskij P. K., Starshinova A. A., Nazarenko M. M., Belyaeva E. N., Chuzhov A. L., Alekseev D. Yu., Pavlova M. V. Efficiency of treatment of drugresistant tuberculosis in patients with different comorbid status Meditsinskij Al'yans. 2022; 10 (1): 6–15. doi: https://doi.org/10.36422/23076348-2022-10-1-6-15. (in Russian)

5. Savintseva E. V., Isaeva P. V., Nizamova G. F. Tuberculosis and COVID-19: medical and social aspects Tuberkulyoz i Bolezni Lyogkikh. 2022; 100 (3): 13–17. doi: https://doi.org/10.36422/23076348-2022-10-1-6-15. (in Russian).

6. Vasil'eva I. A., Samojlova A. G., Zimina V. N., Lovacheva O. V., Abramchenko A. V. Tuberculosis chemotherapy in Russia — the story continues. Tuberkulyoz i Bolezni Lyogkikh. 2023; 101 (2): 8–12. doi: http://doi.org/10.58838/2075–1230-2023-101-2-8-12. (in Russian).

7. Tsybikova Eh.B. Tuberculosis combined with HIV infection in Russia before and during the COVID-19 pandemic. VICH-infektsiya i immunosupressii. 2022; 14 (4): 29–35. doi: http://dx.doi.org/10.22328/2077-9828-2022-14-4-29-35. (in Russian)

8. Mazina N. K., Mazin P. V. Meta-analytical approach to assessing the clinical efficacy of the infusion succinate-containing drug Remaxol in liver pathology of various genesis. Antibiot Khimioter = Antibiotics and Chemotherapy. 2015; 60 (11–12): 43–49. (in Russian)

9. Shumatova T. A., Kovalenko D. V. The role of genes of the second phase of xenobiotic detoxification in the pathogenesis of multifactorial diseases Tikhookeanskij Meditsinskij Zhurnal. 2021; 4:16–20. doi: http://dx.doi.org/10.34215/1609-1175-2021-4-16-20.

10. Sychev D. A. A patient's genetic characteristics may influence the efficacy and safety profile of a drug. Bezopasnost' i Risk Farmakoterapii. 2024;12 (2): 127–131. doi: https://doi.org/10.30895/2312-7821-2024-12-2-127-131. (in Russian)

11. Alymenko M. A., Valiev R. Sh., Valiev N. R., Polonikov A. V., Tragira I. N., Sheenkov N. V. Association of polymorphic variants of genes encoding enzymes for xenobiotic and cytokine biotransformation with lung tissue destruction in patients with tuberculosis Tuberkulyoz i Bolezni Lyogkikh. 2022; 100 (8): 25–30. doi: http://doi.org/10.21292/2075-1230-2022-100-8-25-30. (in Russian)